Ocera Therapeutics Raises $25.2 Million in Public Offering
10 juil. 2014 08h33 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., July 10, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) ("Ocera") today announced that it has priced an underwritten public offering of 4,200,000 shares of its common...
Ocera Therapeutics Announces Proposed Public Offering of Common Stock
09 juil. 2014 16h01 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., July 9, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) ("Ocera" or "the Company") today announced that it intends to offer and sell, subject to market and other...
Ocera Reports Third Quarter Business Update and Financial Results
13 nov. 2013 17h00 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., Nov. 13, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a biopharmaceutical company focused on innovative therapeutics for orphan liver disease, announced today...
Ocera Therapeutics to Present at BIO Investor on October 8, 2013
25 sept. 2013 05h10 HE
|
Ocera Therapeutics, Inc.
SAN DIEGO, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that...
Ocera Announces Post-Merger Closure of Quebec Research Site
17 sept. 2013 16h20 HE
|
Ocera Therapeutics, Inc.
SAN DIEGO, Sept. 17, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focusing on acute and chronic orphan liver diseases, today announced a...
Jeryl L. Hilleman Joins Ocera Therapeutics as Chief Financial Officer
03 sept. 2013 05h10 HE
|
Ocera Therapeutics, Inc.
SAN DIEGO, Sept. 3, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Jeryl...
Ocera Therapeutics to Report Second Quarter 2013 Financial Results
26 juil. 2013 05h10 HE
|
Ocera Therapeutics, Inc.
SAN DIEGO, July 26, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) today announced that the Company will report second quarter 2013 financial results after the close of the market on...
Ocera Therapeutics Announces Completion of Merger With Tranzyme
15 juil. 2013 12h04 HE
|
Ocera Therapeutics, Inc.
SAN DIEGO, July 15, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. ("Ocera"), a clinical stage biopharmaceutical company developing novel therapeutics for orphan liver diseases, and Tranzyme, Inc....
Tranzyme Pharma Announces First Quarter 2013 Financial Results
09 mai 2013 16h30 HE
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., May 9, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) ("Tranzyme"), a biopharmaceutical company focused on discovering, developing and commercializing novel,...